Latest Intensive insulinotherapy Stories

Generex Biotechnology has reached the enrollment milestone of more than 200 subjects in the company's pivotal Phase III clinical trial of Generex Oral-lyn, its proprietary prandial oral insulin spray product. The Phase III study will involve up to 750 subjects with Type-1 diabetes mellitus. There are 74 sites in the US, Canada, Bulgaria, Poland, Romania, Russia and Ukraine actively screening and enrolling subjects. The objective of this long-term study is to compare the efficacy of Generex...

Generex Biotechnology has initiated dosing of over one hundred patients in the company's pivotal Phase III clinical trial of Generex Oral-lyn, its flagship proprietary oral insulin spray product. The Phase III study will involve up to 750 patients with Type-1 Diabetes Mellitus centers in the US, Canada, Russia, and Eastern Europe. Dosing of patients is now underway at 31 clinical trial sites in the US, Canada, Russia, and Ukraine. The objective of the six-month study is to compare the...

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - A new device that monitors blood sugar constantly and lets the patient pump insulin right away if needed might greatly simplify life for people with diabetes, experts told a meeting on Monday. The Medtronic Inc. device combines an insulin pump and a continuous blood-monitoring system. It sounds an alarm if blood sugar goes out of safe ranges. Patients are clamoring to test and use the device, researchers for the...

By David Douglas NEW YORK (Reuters Health) - Inhaled insulin offers patients with type 1 diabetes the potential of avoiding pre-meal injections -- without any loss of diabetes control, a study shows. "This can improve their quality of life, " Dr. Jay S. Skyler, of the University of Miami, who led the study, told Reuters Health. In the study, taking an inhaled form of insulin before meals with insulin injections at other times during the day provided blood sugar control comparable to that of...